Acadia Pharmaceuticals Inc

ACAD

Equity

ISIN US0042251084 / Valor 1184425

NASDAQ (2024-11-20)

USD 16.27+0.37%

Acadia Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Acadia Pharmaceuticals Inc is a healthcare company that has been a leader in providing essential solutions for individuals with specific medical conditions for over three decades. The company is known for pioneering the first and only approved therapies for hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome. Acadia's current clinical-stage developments are focused on addressing Prader-Willi syndrome, Alzheimer’s disease psychosis, and neuropsychiatric symptoms in CNS disorders.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Acadia Pharmaceuticals Inc. reported total net product sales of $242.0 million for the second quarter of 2024, marking a 46% increase year-over-year. This growth was driven by an 11% year-over-year increase in NUPLAZID net sales and an 11% sequential growth in DAYBUE net sales.

Research and Development Expenses

For the second quarter of 2024, Acadia Pharmaceuticals Inc. reported research and development expenses of $76.2 million, up from $58.8 million in the same period of 2023. The increase was primarily due to higher costs associated with ACP-101, ACP-204, and early-stage programs.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for Acadia Pharmaceuticals Inc. were $117.1 million in the second quarter of 2024, compared to $96.0 million in the same quarter of 2023. The rise in expenses was mainly due to upfront costs related to a new consumer activation program and increased marketing costs to support DAYBUE.

Net Income

Acadia Pharmaceuticals Inc. reported a net income of $33.4 million, or $0.20 per common share, for the second quarter of 2024. This is a significant increase compared to the net income of $1.1 million, or $0.01 per common share, reported in the same period of 2023.

Cash and Investments

As of June 30, 2024, Acadia Pharmaceuticals Inc. had cash, cash equivalents, and investment securities totaling $500.9 million. This is an increase from $438.9 million at the end of December 31, 2023, indicating a strong financial position to support future growth.

Summarized from source with an LLMView Source

Key figures

-29.0%1Y

-15.0%3Y

-64.8%5Y

Performance

55.4%1Y

61.1%3Y

64.3%5Y

Volatility